文献速递神经肿瘤

拉罗替尼治疗TRK融合阳性原发中枢神经系统肿瘤的疗效与安全性

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
PubMed 文献 · Neuro Oncol · 2022-01-01

拉罗替尼是获批用于TRK融合阳性癌症的TRK抑制剂,本研究评估其在TRK融合阳性原发中枢神经系统肿瘤患者中的疗效与安全性;33例患者中客观缓解率为30%(95%CI 16-49),24周疾病控制率73%(95%CI 54-87),治疗相关不良事件20例,3-4级3例,作者认为拉罗替尼显示快速持久缓解、高疾病控制率和良好安全性。

要点

  • 33例TRK融合阳性原发中枢神经系统肿瘤患者,中位年龄8.9岁(范围1.3-79.0岁)。
  • 客观缓解率30%(95%CI 16-49),24周疾病控制率73%(95%CI 54-87)。
  • 治疗相关不良事件20例,其中3-4级3例,未发现新的安全性信号。

核心结论

  • 作者认为,在TRK融合阳性中枢神经系统肿瘤患者中,拉罗替尼表现出快速且持久的缓解、高疾病控制率和良好的安全性。

研究设计与样本

  • 研究从两项临床试验(NCT02637687、NCT02576431)中纳入TRK融合阳性原发中枢神经系统肿瘤患者,主要终点为研究者评估的客观缓解率,至2020年7月共识别33例患者,中位年龄8.9岁(范围1.3-79.0岁)。

主要发现

  • 最常见的组织学类型为高级别胶质瘤(HGG,n=19)和低级别胶质瘤(LGG,n=8)。
  • 所有患者的客观缓解率为30%(95%CI 16-49),24周疾病控制率为73%(95%CI 54-87)。
  • 28例可测量病灶患者中23例(82%)出现肿瘤缩小。
  • 缓解持续时间、无进展生存期和总生存期的12个月率分别为75%(95%CI 45-100)、56%(95%CI 38-74)和85%(95%CI 71-99)。
  • 中位起效时间为1.9个月(范围1.0-3.8个月),治疗持续时间为1.2-31.3+个月。

关键数值与推荐

  • 治疗相关不良事件报告于20例患者,其中3-4级3例,未发现新的安全性信号。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. METHODS: Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). RESULTS: As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3-79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16-49) for all patients. The 24-week disease control rate was 73% (95% CI: 54-87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45-100), 56% (95% CI: 38-74), and 85% (95% CI: 71-99), respectively. Median time to response was 1.9 months (range 1.0-3.8 months). Duration of treatment ranged from 1.2-31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3-4 in 3 patients. No new safety signals were identified. CONCLUSIONS: In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022. PMID: 34850167. doi:10.1093/neuonc/noab274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。